GlaxoSmithKline (GSK.L) missed fourth-quarter earnings forecasts on Wednesday as cheap competition to the British drugmaker’s respiratory medicines offset strong growth in sales of its shingles vaccine.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,